Systematic lymphadenectomy in advanced epithelial ovarian cancer: Two decades of uncertainty resolved

Journal of the National Cancer Institute

Volumn 97, Issue 8, 2005, Pages 548-549

  Chambers, Setsuko K ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER MORTALITY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; EDITORIAL; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; OVARY CANCER; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; UTERINE CERVIX CANCER; CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYST; EPIDEMIOLOGY; INCIDENCE; LYMPH NODE; LYMPHADENECTOMY; LYMPHATIC SYSTEM DISEASE; LYMPHEDEMA; METASTASIS; METHODOLOGY; MULTICENTER STUDY; NOTE; OVARY TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

CARCINOMA; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYSTS; FEMALE; HUMANS; INCIDENCE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC DISEASES; LYMPHATIC METASTASIS; LYMPHEDEMA; MULTICENTER STUDIES; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 17144407272     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji123     Document Type: Editorial

References (11)

1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era; a meta-analysis. J Clin Oncol 2002;20:1248-59.
2. Burghardt E, Pickel H, Lahousen M, Stettner H. Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 1986;155:315-9.
3. Morice P, Joulie F, Rey A, Atallah D, Camatte S, Pautier P, et al. Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. Eur J Gynaecol Oncol 2004;25:169-74.
4. Burghardt E, Winter R. The effect of chemotherapy on lymph node metastases in ovarian cancer. Baillieres Clin Obstet Gynaecol 1989;3:167-71.
5. Di Re F, Baiocchi G, Fontanelli R, Grosso G, Cobellis L, Raspagliesi F, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecol Oncol 1996;62:360-5.
6. Spirtos NM, Gross GM, Freddo JL, Ballon SC. Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy. Gynecol Oncol 1995;56:345-52.
7. Scarabelli C, Gallo A, Zarrelli A, Visentin C, Campagnutta E. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. Gynecol Oncol 1995;56:328-37.
8. Benedetti Panici P, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97:560-6.
9. Isonishi S, Niimi S, Sasaki H, Ochiai K, Yasuda M, Tanaka T. Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer. Gynecol Oncol 2004;93:647-52.
10. Sardi JE, Sananes CE, Giaroli AA, Bermudez A, Ferreira MH, Soderini AH, et al. Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial. Int J Gynecol Cancer 1998;8:441-50.
11. Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB. Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol 2002;20:3944-6.